New device catches debris during heart valve procedure to protect the brain
NCT ID NCT07627984
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a device designed to catch and remove debris that can break loose during transcatheter aortic valve replacement (TAVR), a procedure to replace a narrowed heart valve. The device uses two filters placed in arteries leading to the brain. The trial involved 260 people and measured brain lesions on MRI scans after the procedure. The goal was to see if the device reduces brain injury and improves safety.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cerebral embolic protection device
- What this could lead to
- If it works, this device could make TAVR safer by reducing the risk of brain damage from debris during the procedure.
- What could go wrong
- This is a completed trial with 260 participants, but the device only protects certain brain areas and may not prevent all complications. It is not a treatment for the underlying heart disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
260 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Apr 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥18 years, male or non-pregnant/non-lactating female. 2. Suitable for TAVR and planned to undergo TAVR using an approved transcatheter aortic valve system. 3. TAVR access limited to transfemoral or transapical approach. 4. Imaging-confirmed left common carotid artery diameter of 6.5-10 mm and brachiocephalic artery diameter of 9-15 mm at the site of filter placement. 5. No severe stenosis (\>70%), dilation, dissection, ostial aneurysm, or aneurysm within 3 cm of the aortic origin in the target vessels. 6. Brain imaging evaluable by 3-Tesla magnetic resonance imaging. 7. Willing to comply with protocol-required follow-up assessments. 8. Written informed consent provided by the subject or legal guardian. Exclusion Criteria: 1. Impaired right upper limb blood flow. 2. Intracranial hemorrhage, stroke, or transient ischemic attack within 6 months before procedure. 3. Acute myocardial infarction within 1 month before procedure. 4. Calcification in the intended filter deployment region. 5. Planned pacemaker or defibrillator implantation within 30 days after TAVR. 6. Left ventricular ejection fraction ≤20%. 7. Infective endocarditis, intracardiac/aortic mass, thrombus, or vegetation on echocardiography. 8. Severe occlusive carotid disease requiring concomitant carotid intervention, or carotid stenting/endarterectomy within 6 weeks. 9. Leukopenia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulation disorder. 10. Active peptic ulcer disease or gastrointestinal bleeding within 3 months. 11. Severe allergy or known contraindication to nitinol, stainless steel alloy, or contrast media. 12. Contraindication to antiplatelet and/or anticoagulation therapy, or refusal of blood transfusion. 13. Severe renal insufficiency (serum creatinine \>3.0 mg/dL, eGFR \<30 mL/min, or need for renal replacement therapy). 14. Known psychiatric disease or substance abuse that may interfere with compliance or data interpretation. 15. Life expectancy \<1 year. 16. Active infection requiring concurrent antibiotic therapy. 17. Other clinical conditions preventing compliance with the instructions for use of the investigational device. 18. Concurrent use or planned use of another investigational device or drug during the study period. 19. Severe tortuosity of right upper extremity vessels or inability to accommodate a 6 F sheath. 20. Contraindication to MRI, including implanted pacemaker/defibrillator, metal implants, metal fragments, clips, or intracranial/ocular implanted devices.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiamen Cardiovascular Hospital Xiamen University
Xiamen, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can aggressive blood pressure treatment slow aortic valve disease?
- Why do animal heart valves wear out? immune system under investigation
- One scan to rule them all? new CT aims to replace multiple heart tests
- Which heart valve design wins for small aortic openings?
- AI may spot dangerous aortic growth before it happens
- Can a less invasive valve replacement tame a failing aortic valve?